NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in Hi R SMM
- Active, not recruiting
- Dec 11, 2014
- 1 min read
Updated: May 23, 2022
NCT02279394: E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
Sponsor
Dana-Farber Cancer Institute
Collaborators
Bristol-Myers Squibb
Celgene
Blood Cancer Research Partnership
Multiple Myeloma Research Consortium
The Leukemia and Lymphoma Society
Multiple Locations
This research study is aimed to determine the proportion of high risk smoldering multiple myeloma patients who are progression free at 2 years after receiving elotuzumab, lenalidomide and dexamethasone combination therapy.
ClinicalTrials.gov Identifier: NCT02279394
Official Title: E- PRISM: Precision Intervention Smoldering Myeloma: Phase II Trial of Combination of Elotuzumab, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma
First Posted : October 31, 2014
Click here for details on ClinicalTrials.gov
Drug: Elotuzumab
Drug: Lenalidomide
Drug: Dexamethasone
Locations
United States, Colorado
United States, Connecticut
United States, Illinois
United States, Maine
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, North Carolina